Literature DB >> 10732757

Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.

S Kakolyris1, S B Fox, M Koukourakis, A Giatromanolaki, N Brown, R D Leek, M Taylor, I M Leigh, K C Gatter, A L Harris.   

Abstract

Angiogenesis, the formation of new vessels, has been demonstrated to be an indicator of prognosis in breast cancer patients. The extent of differentiation of the tumour vessels may affect access of peripheral white cells and egress or invasion of tumour cells. This has not been assessed in relation to tumour microvessel density or other variables and may be a marker of vascular remodelling. LH39 is a monoclonal antibody recognizing an epitope located at the lamina lucida of mature small veins and capillaries but not in newly formed vessels. To study vascular differentiation in breast tumours, we examined the vascular maturation index (VMI) in 12 normal and 50 breast carcinomas and this was correlated with different clinicopathological variables including angiogenesis. Mature vessels were defined by staining with antibodies to both LH39 and to CD31, using double immunohistochemistry, whereas immature vessels stained only for CD31. VMI was defined as the % fraction of mature vessels (LH39-positive) / total number of vessels (CD31-positive). The VMI was significantly higher in normal (54-68.5%; median 66.5%) than in tumours (0-47%; median 8.8%) (P = 0.0005). There was a significant inverse correlation between the tumour VMI and nodal status (Fisher's exact test, P = 0.01) and between high VMI and low thymidine phosphorylase (TP) expression (Mann-Whitney U-test, P= 0.01). No significant association between VMI and tumour size, oestrogen receptor, epidermal growth factor receptor, grade, angiogenesis, patient age, or E-selectin was seen. There was a significant reduction in relapse-free survival (P = 0.01) with high angiogenesis. These findings show that the VMI gives new information on the mechanism of tumour angiogenesis independently from microvessel quantitation, there is a wide variation in the differentiation of tumour vasculature but the degree of capillary differentiation is not associated with quantitative angiogenesis. The VMI identifies a subset of patients who have a high chance of regional node involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732757      PMCID: PMC2374391          DOI: 10.1054/bjoc.1999.1010

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  46 in total

Review 1.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis.

Authors:  C H Blood; B R Zetter
Journal:  Biochim Biophys Acta       Date:  1990-06-01

Review 2.  The role of basement membrane in angiogenesis and tumor growth.

Authors:  D S Grant; M C Kibbey; J L Kinsella; M C Cid; H K Kleinman
Journal:  Pathol Res Pract       Date:  1994-10       Impact factor: 3.250

Review 3.  Integrins as dynamic regulators of vascular function.

Authors:  F W Luscinskas; J Lawler
Journal:  FASEB J       Date:  1994-09       Impact factor: 5.191

Review 4.  Oestrogen and endothelial cell angiogenic activity.

Authors:  H W Schnaper; K A McGowan; S Kim-Schulze; M C Cid
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-03       Impact factor: 2.557

Review 5.  Tumour angiogenesis and prognosis.

Authors:  S B Fox
Journal:  Histopathology       Date:  1997-03       Impact factor: 5.087

6.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; D F Hayes; J Folkman
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

7.  Microvessel quantitation and prognosis in invasive breast carcinoma.

Authors:  S Bosari; A K Lee; R A DeLellis; B D Wiley; G J Heatley; M L Silverman
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

8.  Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.

Authors:  S B Fox; R D Leek; M P Weekes; R M Whitehouse; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-11       Impact factor: 7.996

9.  Inhibition of angiogenesis through modulation of collagen metabolism.

Authors:  D Ingber; J Folkman
Journal:  Lab Invest       Date:  1988-07       Impact factor: 5.662

10.  Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.

Authors:  S B Fox; A Moghaddam; M Westwood; H Turley; R Bicknell; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-06       Impact factor: 7.996

View more
  13 in total

1.  Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer.

Authors:  Angela M Jarrett; Meghan J Bloom; Wesley Godfrey; Anum K Syed; David A Ekrut; Lauren I Ehrlich; Thomas E Yankeelov; Anna G Sorace
Journal:  Math Med Biol       Date:  2019-09-02       Impact factor: 1.854

2.  Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

Authors:  Michael Millward; Paul Mainwaring; Alain Mita; Kristine Federico; G K Lloyd; Natasha Reddinger; Steffan Nawrocki; Monica Mita; Matthew A Spear
Journal:  Invest New Drugs       Date:  2011-02-16       Impact factor: 3.850

3.  Adipose Stroma Accelerates the Invasion and Escape of Human Breast Cancer Cells from an Engineered Microtumor.

Authors:  Yoseph W Dance; Tova Meshulam; Alex J Seibel; Mackenzie C Obenreder; Matthew D Layne; Celeste M Nelson; Joe Tien
Journal:  Cell Mol Bioeng       Date:  2021-08-24       Impact factor: 3.337

4.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

5.  Anti-angiogenesis therapies: their potential in cancer management.

Authors:  Andrew Eichholz; Shairoz Merchant; Andrew M Gaya
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

6.  Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Constantinos Simopoulos; Alexandros Polychronidis; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Angiogenesis in salivary carcinomas with and without myoepithelial differentiation.

Authors:  A F Costa; A P D Demasi; V L L Bonfitto; J F L Bonfitto; C Furuse; V C Araújo; K Metze; A Altemani
Journal:  Virchows Arch       Date:  2008-09-16       Impact factor: 4.064

Review 8.  Vascular disrupting agents in clinical development.

Authors:  P Hinnen; F A L M Eskens
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

9.  Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes.

Authors:  François Pepin; Nicholas Bertos; Julie Laferrière; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Greg Finak; Sarkis Meterissian; Michael T Hallett; Morag Park
Journal:  Breast Cancer Res       Date:  2012-08-20       Impact factor: 6.466

Review 10.  Breast tumour angiogenesis.

Authors:  Stephen B Fox; Daniele G Generali; Adrian L Harris
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.